MedPath

The study of the impact of changes in surface antigens on eosinophils after treatment in patients with asthma

Not Applicable
Conditions
Patients with asthma and asthma suspicion
Registration Number
JPRN-UMIN000052207
Lead Sponsor
Kurume University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
85
Inclusion Criteria

Not provided

Exclusion Criteria

1) current and ex-heavy smokers (>10pack-year) 2) Immunosuppressive patients with active cancer and HIV infections 3) History of patients with lung resections 4) During severe or fatal asthma exacerbations 5) Other chronic respiratory diseases

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The low CD62- and CD34-positive eosinophils at pre-treatment and early improvement of CD62- and CD34-positive eosinophils after treatment are estimable biomarkers of clinical remission of asthma.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath